Bioethicists Call for Oversight of Direct-to-Consumer “Neurotechnologies” Promising Unproven Benefits
Penn bioethicist proposes a working group to study and monitor poorly regulated products, predicted to top $3 billion by 2020
The marketing of direct-to-consumer “neurotechnologies” can be enticing: apps that diagnose a mental state, and brain devices that improve cognition or “read” one’s emotional state. However, many of these increasingly popular products aren’t fully supported by science and have little to no regulatory oversight, which poses potential health risks to the public. Two bioethicists from Penn Medicine and the University of British Columbia suggest the creation of a working group that would further study, monitor, and provide guidance for this growing industry – which is expected to top $3 billion by 2020.
“There’s a real thirst for knowledge about the efficacy of these products from the public, which remains unclear because of this lack of oversight and gap in knowledge,” said lead author Anna Wexler, PhD, an instructor in the department of Medical Ethics and Health Policy at the Perelman School of Medicine at the University of Pennsylvania. “We believe a diverse, dedicated group would help back up or refute claims made by companies, determine what’s safe, better understand their use among consumers, and address possible ethical concerns.”
Click here to read more.
INS 14th World Congress
May 25-30, 2019; Sydney
12th Annual Cervical Spine Research Society Hands-on Cadaver Course
May 30-June 1, 2019; St. Louis
Brain Tumor Biotech Summit
June 7, 2019; New York
Minimally Invasive Cranial Neurosurgery: Recent Technical Advances With Hands-On Laboratory
June 7-8, 2019; New York
The 25th Annual Meeting of the Organization for Human Brain Mapping (OHBM 2019)
June 9-13, 2019; Rome